Monofer (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofer, is an iron supplement presented as a solution for injection for intravenous use. It treats iron deficiency anemia in adults and pediatric patients where oral iron is ineffective or not tolerated, providing elemental iron for incorporation into hemoglobin and myoglobin to rapidly replenish depleted iron stores.

GNH USA supplies Monofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Monofer is used to treat iron deficiency anemia, a condition characterized by insufficient iron for normal red blood cell production. - Iron deficiency anemia: restores hemoglobin levels in patients with inadequate iron stores. - Chronic kidney disease‑associated anemia: provides intravenous iron when oral therapy fails. - Preoperative anemia: corrects iron deficiency before surgery to reduce the need for blood transfusion.

Monofer may cause a range of adverse reactions, most of which are related to the infusion process or iron overload.

Common Side Effects: - Nausea - Headache - Injection site pain - Transient hypertension

Serious or Rare Side Effects: - Anaphylaxis - Severe hypotension - Iron overload

Before administering Monofer, several precautions should be observed to ensure patient safety. - Assess iron status: confirm iron deficiency before administration. - Monitor for hypersensitivity: observe patient during and after infusion. - Avoid rapid infusion: follow recommended infusion rate to reduce cardiovascular events. - Use with caution in renal impairment: adjust monitoring as needed. - Pregnancy and lactation: use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Monofer can interact with other medications; awareness of these interactions helps manage patient therapy.

Major Interactions (Avoid): - Concurrent use of other IV iron products: may cause iron overload. - Concurrent erythropoiesis‑stimulating agents at high doses: risk of hypertension. - Anticoagulants: increased risk of bleeding with infusion reactions.

Moderate Interactions (Monitor Closely): - Oral iron supplements: may interfere with absorption if given simultaneously; separate administration times. - Vitamin C supplements: can increase iron release and risk of oxidative stress. - Medications causing hypotension (e.g., antihypertensives): monitor blood pressure during infusion.